Advertisement for orthosearch.org.uk
Results 1 - 1 of 1
Results per page:
Applied filters
Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 90-B, Issue SUPP_I | Pages 122 - 122
1 Mar 2008
Mahoney M Guerin J Bourne R MacDonald S McCalden R
Full Access

The Genesis II total knee prosthesis was a successor to the Genesis I TKR in which three degrees of external rotation was built into the femoral component to improve patellofemoral tracking and eliminate rotational incongruity. The midterm (minimum five year) results of three hundred and forty-three Genesis II cemented components were reviewed in three hundred and twenty-four patients. Kaplan-Meier survivorship was 98% at a mean 7.6 years.

The focus of this study was to analyze the minimum five- year results of patients receiving either a cruciate-retaining, posterior stabilizing, or mobile bearing Genesis II TKR. Further analysis was performed to delineate differences between subsets of this population.

Data from a consecutive series of three hundred and twenty-four patients receiving three hundred and sixty-seven Genesis II TKR’s between February 1996 and July 1999 was collected. Patients were evaluated pre-operatively, at six weeks, three months, six months and annually thereafter, using the Knee Society Clinical Rating System and the Western Ontario MacMaster Osteoarthritis Index. A Kaplan-Meier Survivorship was performed on the consecutive series. Statistical analyses were used to delineate significant differences between subsets of patients.

There were three hundred and sixty-seven procedures (one hundred and sixty-nine cruciate-retaining, one hundred and sixty-six posterior stabilized and six mobile bearing designs) performed on three hundred and twenty-four patients. At the time of evaluation, forty-five (13%) patients were deceased, twenty-four (7%) patients were unavailable for evaluation and nine (2%) knees had been revised. A 98% implant survivor-ship was calculated at a mean time of 7.6 years.

These are the first mid-term (minimum five year) clinical results of the Genesis II TKR, which continues to function well. Kaplan-Meier survivorship was 98% at a mean 7.6 years.